Genetic Testing for Cancer Risk in Women Ages 25 to 39 During Gynecology Visits

What this Trial Is About

This research study is focused on evaluating the feasibility and acceptance of offering genetic testing for cancer-related genes to female patients during gynecology clinic visits. The aim is to determine how many patients undergo genetic testing and how many have disease-related genetic variants without needing to see specialized providers or meet strict criteria. The study is sponsored by NYU Langone Health and targets women aged 25 to 39 years. Participants will be offered the Natera Empower hereditary cancer panel test, which is a saliva-based genetic test. Those who test positive for actionable pathogenic variants will be referred to specialists such as medical oncologists, gynecologic oncologists, or breast surgeons for discussions about risk-reduction options. All participants can access genetic counseling, which the research team can arrange if desired. There are two groups those who complete the genetic screening and those who decline it. During the study, participants will provide saliva samples for genetic testing at the point of care. Researchers will track the number of participants who complete testing and identify those with pathogenic variants over a period of up to nine months. Participants may receive referrals and counseling based on their results. The study allows healthy volunteers and runs through the end of 2027, with no masking or randomization involved.

Universal Genetic Testing for Cancer Risk Reduction